Abstract
Population-level survival has increased for a number of hematologic malignancies.1–3 Multiple myeloma, in particular, has seen improved survival both in clinical trials4–8 and on the population level.3,9–11 However, it is not known whether the changes in survival for myeloma have extended to other, less common plasma cell or plasmacytoid malignancies such as lymphoplasmacytic lymphoma (LPL, includes Waldenström’s macroglobulinemia (WM)), plasma cell leukemia (PCL), and solitary plasmacytoma (SP). Only a few population level studies of survival are available on LPL,12,13 PCL,14,15 and SP,16 with little information on changes in survival in the past decade.
...
...
| Original language | English |
|---|---|
| Journal | Haematologica |
| Volume | 102 |
| Issue number | 6 |
| Pages (from-to) | 229-232 |
| Number of pages | 4 |
| ISSN | 0390-6078 |
| DOIs | |
| Publication status | Published - 01.01.2017 |
Funding
this work was supported in part by a grant from the German Cancer Aid (Deutsche Krebshilfe, no. 108257) and a visiting scientist grant from the German Cancer Research Center to DP.
Research Areas and Centers
- Research Area: Center for Population Medicine and Public Health (ZBV)
